Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Country Manager Austria, the Director, Medical Affairs, Austria is the medical leader responsible for defining and executing the local medical strategy RevMed portfolio and launches. This role serves as the medical voice within the Austria Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs.

This leader will ensure that Austria medical considerations are embedded in the regional medical strategy and plans and will partner with the Country Manager and crossfunctional teams, as well as the Sr Dir Medical Affairs Midsized Markets and VP Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the Austria medical team and work closely with the Midsized Markets crossfuncitonal and cross-country teams, Global and Regional Medical Affairs teams across Med Affairs functions. Required Skills, Experience and Education: Act as the Medical Affairs lead for Austria, accountable for local medical strategy, execution, and impact across the oncology portfolio.

Translate global medical and clinical strategies into locally relevant medical plans aligned with country regulations and clinical practice. Build and maintain strong relationships with national and regional key opinion leaders, oncology networks, academic institutions, and scientific societies. Lead scientific exchange, advisory boards, investigator and other external meetings, press conferences, and congress engagement at country level.

Collaborate effectively with Midsized Markets, Regional and Global teams by contributing to overall medical affairs strategy, strongly partnering with local, regional and global clinical development and operations teams. Drive local medical strategy across pre-launch, launch, and post-launch phases. Provide local medical expertise on evidence generation activities including local studies, real-world evidence initiatives, and investigator-initiated research (where permitted).

Ensure effective execution of publication plans and scientific communication activities. Lead medical launch readiness for oncology products, including training, scientific materials, and field medical engagement plans. g.

representing and defining evidence and value of innovation at oral HTA hearings. Support lifecycle management activities including new indications, label updates, and competitive positioning. Work closely with Market Access, Commercial, Regulatory, Safety, and Corporate Affairs teams to ensure aligned and compliant execution of country plans.

Provide medical review and approval of non-promotional materials in accordance with local regulations and company policies. Build, lead, and develop the country Medical Affairs team when/if applicable, including Medical advisors and MSLs. Establish medical processes, governance, and ways of working as part of the country build-out.

Foster a culture of scientific rigor, compliance, and collaboration.